Amylyx Pharmaceuticals entered into a Manufacturing and Supply Agreement with Bachem Americas to supply avexitide drug substance for commercial use starting in 2028, alongside a term sheet with Polypeptide Group AG requiring a $30 million upfront fee for capacity reservation. Both agreements establish non-exclusive supply arrangements with minimum purchase quantities and annual price adjustments effective January 1, 2028. The company operates in the pharmaceutical industry, focusing on drug development.

Amylyx Pharmaceuticals entered into an underwriting agreement on August 19, 2026, to sell 14,090,000 shares of common stock at $35.50 per share. The company granted underwriters a 30-day option to purchase up to 2,113,500 additional shares. Net proceeds are expected to be approximately $471.7 million, or $542.5 million if the option is exercised in full. The offering is scheduled to close on August 21, 2026. Amylyx intends to use the net proceeds to fund the potential commercial launch of avexitide in the United States, secure manufacturing capacity, and support research and development activities. This company operates in the biopharmaceutical industry, focusing on drug discovery and development for neurodegenerative diseases.

Amylyx Pharmaceuticals announced that its Phase 3 LUCIDITY trial met all primary and secondary endpoints, demonstrating a statistically significant 55% reduction in Level 2 and Level 3 hypoglycemic events compared to placebo for avexitide in patients with post-bariatric hypoglycemia. The drug was generally well-tolerated with no treatment-related serious adverse events. The company is preparing for New Drug Application submission to the FDA by the end of 2026, aiming for a potential commercial launch in 2027 if approved. Amylyx Pharmaceuticals operates in the biopharmaceutical industry and develops therapies for rare diseases.

Amylyx Pharmaceuticals announced positive topline results from the Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia. The study enrolled 78 participants and met its primary endpoint, demonstrating a 55% reduction in Level 2 and 3 hypoglycemic events compared to placebo (p=0.000003). Avexitide was well-tolerated with no serious adverse events related to treatment. The company plans to submit a New Drug Application to the FDA by the end of 2026, aiming for potential commercialization in 2027 if approved. Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare diseases.

Amylyx Pharmaceuticals reported a net loss of $43.4 million, or $0.39 per share, for the quarter ended June 30, 2026, compared to a $41.4 million loss in the prior year period. Research and development expenses decreased to $23.8 million from $27.2 million, primarily due to reduced spending on AMX0035 for progressive supranuclear palsy, partially offset by increased costs for avexitide clinical development. Selling, general, and administrative expenses rose to $21.9 million from $15.6 million, driven by higher legal fees and commercial strategic investments. The company held $250.8 million in cash equivalents and short-term investments at quarter-end, with a projected cash runway extending into 2028. Clinically, the final participant completed the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial for avexitide in post-bariatric hypoglycemia, with topline data anticipated in late August or early September 2026. Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for rare endocrine and neurodegenerative diseases.